Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Gastroenterología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 25 de oct de 2023
ID: NCT06052059
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
INTERVENTIONAL
Inicio: 30 de oct de 2019
ID: NCT04133909
Completado
Fase 3
ClinicalTrials.gov
MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC
INTERVENTIONAL
Inicio: 9 de jul de 2019
ID: NCT03905330
Terminado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease
INTERVENTIONAL
Inicio: 6 de ene de 2020
ID: NCT04173273
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
INTERVENTIONAL
Inicio: 1 de ene de 2012
ID: NCT01492426
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
INTERVENTIONAL
Inicio: 7 de dic de 2017
ID: NCT03345849
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Open-label, Basket, LTE Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis
INTERVENTIONAL
Inicio: 29 de oct de 2024
ID: NCT06663332
Desconocido
ClinicalTrials.gov
Institutional Registry of Liver Transplantation
OBSERVATIONAL
Inicio: 1 de jul de 2016
ID: NCT02839616
Completado
ClinicalTrials.gov
A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C
OBSERVATIONAL
Inicio: 7 de feb de 2012
ID: NCT01492504
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared With BGF Delivered by MDI HFA in Participants With Chronic Obstructive Pulmonary Disease
INTERVENTIONAL
Inicio: 11 de ene de 2024
ID: NCT06075095
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Study With Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects With Chronic Hepatitis C Genotype 1b Infection
INTERVENTIONAL
Inicio: 1 de may de 2012
ID: NCT01581203
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
INTERVENTIONAL
Inicio: 10 de jun de 2018
ID: NCT03755791
Desconocido
ClinicalTrials.gov
How Does the EUS-guided Through-the-needle Microforceps Biopsy Improve Diagnosis of Pancreatic Cystic Lesions: A Multicenter Prospective Study
OBSERVATIONAL
Inicio: 22 de oct de 2019
ID: NCT04140435
Completado
Fase 4
ClinicalTrials.gov
A 54 Week, Randomized, Double-blind, Parallel-group, Multicenter Study Evaluating the Long-term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension
INTERVENTIONAL
Inicio: 1 de feb de 2008
ID: NCT00631917
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
INTERVENTIONAL
Inicio: 18 de abr de 2018
ID: NCT03383458
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.
INTERVENTIONAL
Inicio: 1 de jul de 2007
ID: NCT00471146
Completado
ClinicalTrials.gov
A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in Which Peginterferon Lambda-1a (BMS-914143) Was Administered for the Treatment of Chronic Hepatitis C
OBSERVATIONAL
Inicio: 1 de mar de 2012
ID: NCT01525810
Desconocido
ClinicalTrials.gov
Liver Injury in Hospitalized Patients With COVID-19 in Latin America: Clinical Characteristics and Prognostic Factors
OBSERVATIONAL
Inicio: 15 de abr de 2020
ID: NCT04358380
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.
INTERVENTIONAL
Inicio: 11 de nov de 2020
ID: NCT04583423
Completado
ClinicalTrials.gov
Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated With Nucleoside/Nucleotide Monotherapy for Patients With Chronic HBV Infection: The REALM Study
OBSERVATIONAL
Inicio: 18 de dic de 2006
ID: NCT00388674
Anterior
1
...
26
27
28
...
434
Siguiente
Filtros